Literature DB >> 10082562

Transcriptional activation by ETS and leucine zipper-containing basic helix-loop-helix proteins.

G Tian1, B Erman, H Ishii, S S Gangopadhyay, R Sen.   

Abstract

The immunoglobulin mu heavy-chain gene enhancer contains closely juxtaposed binding sites for ETS and leucine zipper-containing basic helix-loop-helix (bHLH-zip) proteins. To understand the mu enhancer function, we have investigated transcription activation by the combination of ETS and bHLH-zip proteins. The bHLH-zip protein TFE3, but not USF, cooperated with the ETS domain proteins PU.1 and Ets-1 to activate a tripartite domain of this enhancer. Deletion mutants were used to identify the domains of the proteins involved. Both TFE3 and USF enhanced Ets-1 DNA binding in vitro by relieving the influence of an autoinhibitory domain in Ets-1 by direct protein-protein associations. Several regions of Ets-1 were found to be necessary, whereas the bHLH-zip domain was sufficient for this effect. Our studies define novel interactions between ETS and bHLH-zip proteins that may regulate combinatorial transcription activation by these protein families.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10082562      PMCID: PMC84089          DOI: 10.1128/MCB.19.4.2946

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  27 in total

1.  Precise alignment of sites required for mu enhancer activation in B cells.

Authors:  B S Nikolajczyk; B Nelsen; R Sen
Journal:  Mol Cell Biol       Date:  1996-08       Impact factor: 4.272

2.  Context dependent transactivation domains activate the immunoglobulin mu heavy chain gene enhancer.

Authors:  B Erman; R Sen
Journal:  EMBO J       Date:  1996-09-02       Impact factor: 11.598

3.  A three-protein-DNA complex on a B cell-specific domain of the immunoglobulin mu heavy chain gene enhancer.

Authors:  E Rao; W Dang; G Tian; R Sen
Journal:  J Biol Chem       Date:  1997-03-07       Impact factor: 5.157

4.  Modulation of transcription factor Ets-1 DNA binding: DNA-induced unfolding of an alpha helix.

Authors:  J M Petersen; J J Skalicky; L W Donaldson; L P McIntosh; T Alber; B J Graves
Journal:  Science       Date:  1995-09-29       Impact factor: 47.728

5.  TFE3 contains two activation domains, one acidic and the other proline-rich, that synergistically activate transcription.

Authors:  S E Artandi; K Merrell; N Avitahl; K K Wong; K Calame
Journal:  Nucleic Acids Res       Date:  1995-10-11       Impact factor: 16.971

6.  Assembly and function of a TCR alpha enhancer complex is dependent on LEF-1-induced DNA bending and multiple protein-protein interactions.

Authors:  K Giese; C Kingsley; J R Kirshner; R Grosschedl
Journal:  Genes Dev       Date:  1995-04-15       Impact factor: 11.361

7.  The absence of the transcription activator TFE3 impairs activation of B cells in vivo.

Authors:  K Merrell; S Wells; A Henderson; J Gorman; F Alt; A Stall; K Calame
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

8.  Binding of myc proteins to canonical and noncanonical DNA sequences.

Authors:  T K Blackwell; J Huang; A Ma; L Kretzner; F W Alt; R N Eisenman; H Weintraub
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

9.  Cooperative binding of Ets-1 and core binding factor to DNA.

Authors:  D Wotton; J Ghysdael; S Wang; N A Speck; M J Owen
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

10.  Transactivation of the Moloney murine leukemia virus and T-cell receptor beta-chain enhancers by cbf and ets requires intact binding sites for both proteins.

Authors:  W Sun; B J Graves; N A Speck
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

View more
  17 in total

Review 1.  Transcriptional control by the TGF-beta/Smad signaling system.

Authors:  J Massagué; D Wotton
Journal:  EMBO J       Date:  2000-04-17       Impact factor: 11.598

2.  Phosphorylation represses Ets-1 DNA binding by reinforcing autoinhibition.

Authors:  D O Cowley; B J Graves
Journal:  Genes Dev       Date:  2000-02-01       Impact factor: 11.361

3.  Combinatorial gene control involving E2F and E Box family members.

Authors:  Paloma H Giangrande; Wencheng Zhu; Rachel E Rempel; Nina Laakso; Joseph R Nevins
Journal:  EMBO J       Date:  2004-03-04       Impact factor: 11.598

4.  Auto-inhibition of Ets-1 is counteracted by DNA binding cooperativity with core-binding factor alpha2.

Authors:  T L Goetz; T L Gu; N A Speck; B J Graves
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

5.  Mi2beta shows chromatin enzyme specificity by erasing a DNase I-hypersensitive site established by ACF.

Authors:  Haruhiko Ishii; Hansen Du; Zhaoqing Zhang; Angus Henderson; Ranjan Sen; Michael J Pazin
Journal:  J Biol Chem       Date:  2009-01-21       Impact factor: 5.157

Review 6.  Regulation of endothelial cell development by ETS transcription factors.

Authors:  Stryder M Meadows; Candace T Myers; Paul A Krieg
Journal:  Semin Cell Dev Biol       Date:  2011-09-18       Impact factor: 7.727

Review 7.  Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers.

Authors:  Eric C Kauffman; Christopher J Ricketts; Soroush Rais-Bahrami; Youfeng Yang; Maria J Merino; Donald P Bottaro; Ramaprasad Srinivasan; W Marston Linehan
Journal:  Nat Rev Urol       Date:  2014-07-22       Impact factor: 14.432

8.  Identification of interacting transcription factors regulating tissue gene expression in human.

Authors:  Zihua Hu; Steven M Gallo
Journal:  BMC Genomics       Date:  2010-01-19       Impact factor: 3.969

Review 9.  Review of Ets1 structure, function, and roles in immunity.

Authors:  Lee Ann Garrett-Sinha
Journal:  Cell Mol Life Sci       Date:  2013-01-05       Impact factor: 9.261

10.  Ets-1 is required for the activation of VEGFR3 during latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells.

Authors:  Kimberley D Gutierrez; Valerie A Morris; David Wu; Serge Barcy; Michael Lagunoff
Journal:  J Virol       Date:  2013-04-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.